Latest NeuroPhage Pharmaceuticals Inc. Stories
CAMBRIDGE, Mass., March 20, 2015 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc., today announced that Jonathan Solomon, CEO, will participate on an expert panel, "Neuroscience Therapeutics
CAMBRIDGE, Mass., March 16, 2015 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc., today announced that Richard Fisher, PhD, the Company's Chief Scientific Officer, will present at the 12(th)
--Funds Will Advance Breakthrough Drug Candidate NPT088 into the Clinic-- CAMBRIDGE, Mass., Jan.
CAMBRIDGE, Mass., Nov.
Dr. Hefti to Lead All Clinical Development Efforts and Strategic Initiatives CAMBRIDGE, Mass., Nov.
Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.
--Research Published in the Journal of Molecular Biology-- CAMBRIDGE, Mass., April 22, 2014 /PRNewswire/ -- Researchers from NeuroPhage
--Funds Will Advance Novel Approach for Treatment of Alzheimer's Disease and Other Diseases of Protein Aggregation-- CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- NeuroPhage Pharmaceuticals,